Bekele, Delamo I. http://orcid.org/0000-0002-1907-0864
Cheng, Elizabeth
Reimold, Andreas
Geier, Christian http://orcid.org/0000-0002-2971-1485
Ganuthula, Kavya
Walsh, Jessica A. http://orcid.org/0000-0002-4563-0845
Clegg, Daniel O. http://orcid.org/0000-0003-1494-2376
Dubreuil, Maureen http://orcid.org/0000-0002-6253-1515
Kaushik, Prashant
Ng, Bernard http://orcid.org/0000-0002-0126-1275
Chang, Elizabeth
Duong, Ryan http://orcid.org/0000-0002-3763-6884
Park, Jina
Kerr, Gail S. http://orcid.org/0000-0002-4930-3235
Funding for this research was provided by:
Novartis Pharma
Article History
Received: 16 August 2021
Accepted: 4 October 2021
First Online: 1 November 2021
Declarations
:
: The other authors have disclosed no conflicts of interest. Dr. Kerr has received current and prior grant funding from Novartis, BMS and Pfizer. She currently serves on the advisory board for Janssen. Dr. Walsh has received consulting fees from AbbVie, Lilly, Novartis and UCB (all less than $10,000). She has also received research funding from AbbVie and Pfizer. Dr. Clegg has received VA Merit Review funding. Dr. Reimold has served as a consultant for Lilly (less than $10,000).
: Approval obtained by the local Institutional Review Board at each participating site, and by the independent Scientific Ethics and Advisory Committee for the Department of Veterans Affairs (VA) Program to Understand the Longterm Outcomes in SpondyloARthritis registry (PULSAR). Ethics Approval MIRB number: 01138. Initial approval: 08/28/2008.